Annals of gastroenterology

How GLP-1 receptor drugs affect upper digestive tract exam results: a review and combined analysis

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗

Updated

Abstract

A systematic review and meta-analysis evaluated the impact of glucagon-like peptide-1 receptor agonists on upper gastrointestinal endoscopy outcomes.

  • GLP-1 receptor agonists may delay gastric emptying, which is a concern during upper GI endoscopy.
  • The analysis aimed to assess procedural outcomes specifically related to the use of GLP-1 RAs.
  • Findings from this review could inform clinicians about potential risks when administering GLP-1 RAs before endoscopic procedures.

Simplified

Funding

Competing interests

No competing interests reported.
PubMed

Related papers

Jul '25
Effects of GLP-1 receptor drugs on upper digestive tract examinations: updated review and analysis
top 20% journal
cited by 5 papers
systematic review
Mar '25
Safety of Digestive Tract Endoscopy in Patients Using Glucagon-like Peptide-1 Medicines: A Comprehensive Review
top 30% journal
cited by 6 papers
journal article
Nov '22
Folic acid supplements and malaria risk and severity in people using antifolate malaria drugs in affected areas
cited by 30 papers
systematic review
Dec '24
Use of glucagon-like peptide-1 receptor drugs and the risk of leftover stomach contents and choking during digestive system exams
top 5% journal
cited by 31 papers
systematic review
Jun '26
Lung-related side effects linked to GLP-1 receptor agonist medications: a review of respiratory safety concerns
journal article
Oct '24
Glucagon-like peptide-1 receptor agonists and their impact on endoscopy results: a systematic review and meta-analysis
top 5% journal
cited by 22 papers
systematic review
May '26
Safety of Glucagon-Like Peptide-1 Receptor Agonists Before Upper Endoscopy: A Review and Analysis
journal article
Aug '24
How Glucagon-Like Peptide-1 Receptor Agonists Affect Upper Gut Examinations: A Meta-Analysis
top 2% journal
cited by 35 papers
systematic review
Oct '24
Use of Glucagon-like Peptide-1 Drugs Before Upper Stomach and Throat Exams and the Risk of Breathing Problems or Stopping the Procedure
top 5% journal
cited by 44 papers
journal article
May '26
Glucagon-like peptide-1 receptor agonists and their effects on stomach emptying time: a review and analysis of prospective studies
top 20% journal
journal article

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free

Recent issues from the glp-1 therapies brief

issue #48
Stop the drug, regain the weight: pooled data puts the average rebound at 7%
2 days ago7 studies
issue #47
The brain region that explains why blocking and activating the same receptor both cause weight loss
1 week ago7 studies
issue #46
GLP-1 drugs linked to lower depression and bipolar disorder risk in large genetic study
2 weeks ago7 studies
issue #45
Stopping GLP-1 drugs linked to higher depression and anxiety risk in type 2 diabetes patients
3 weeks ago7 studies
issue #44
Tirzepatide cut all-cause mortality by more than half compared to semaglutide in a 47,000-patient study
4 weeks ago7 studies
issue #43
Semaglutide linked to 21% lower psychiatric hospitalization risk in bipolar disorder patients
5 weeks ago7 studies
issue #42
Tirzepatide users lost 14.7% of body weight vs. 10.8% with semaglutide — but Black and Hispanic patients were overrepresented in the lowest-response group
6 weeks ago8 studies
issue #41
New obesity drug survodutide cut weight by 13% vs 5.4% for placebo in 725 patients
7 weeks ago7 studies
issue #40
GLP-1 users had 3x higher risk of aspiration pneumonia after stroke surgery
8 weeks ago7 studies
issue #39
Semaglutide linked to reduced cigarette craving in 24 smokers
9 weeks ago7 studies
explore the archive
See more issues from the glp-1 therapies brief